PMID- 23365442 OWN - NLM STAT- MEDLINE DCOM- 20130502 LR - 20221207 IS - 1098-5514 (Electronic) IS - 0022-538X (Print) IS - 0022-538X (Linking) VI - 87 IP - 7 DP - 2013 Apr TI - HLA-B*57 versus HLA-B*81 in HIV-1 infection: slow and steady wins the race? PG - 4043-51 LID - 10.1128/JVI.03302-12 [doi] AB - Two human leukocyte antigen (HLA) variants, HLA-B*57 and -B*81, are consistently known as favorable host factors in human immunodeficiency virus type 1 (HIV-1)-infected Africans and African-Americans. In our analyses of prospective data from 538 recent HIV-1 seroconverters and cross-sectional data from 292 subjects with unknown duration of infection, HLA-B*57 (mostly B*57:03) and -B*81 (exclusively B*81:01) had mostly discordant associations with virologic and immunologic manifestations before antiretroviral therapy. Specifically, relatively low viral load (VL) in HLA-B*57-positive subjects (P /= 0.37). In contrast, individuals with HLA-B*81 showed little deviation from the normal set point VL (P > 0.18) while maintaining high CD4 count during early and chronic infection (P = 0.01). These observations suggest that discordance between VL and CD4 count can occur in the presence of certain HLA alleles and that effective control of HIV-1 viremia is not always a prerequisite for favorable prognosis (delayed immunodeficiency). Of note, steady CD4 count associated with HLA-B*81 in HIV-1-infected Africans may depend on the country of origin, as observations differed slightly between subgroups enrolled in southern Africa (Zambia) and eastern Africa (Kenya, Rwanda, and Uganda). FAU - Prentice, Heather A AU - Prentice HA AD - Department of Epidemiology, University of Alabama at Birmingham (UAB), Birmingham, Alabama, USA. FAU - Porter, Travis R AU - Porter TR FAU - Price, Matthew A AU - Price MA FAU - Cormier, Emmanuel AU - Cormier E FAU - He, Dongning AU - He D FAU - Farmer, Paul K AU - Farmer PK FAU - Kamali, Anatoli AU - Kamali A FAU - Karita, Etienne AU - Karita E FAU - Lakhi, Shabir AU - Lakhi S FAU - Sanders, Eduard J AU - Sanders EJ FAU - Anzala, Omu AU - Anzala O FAU - Amornkul, Pauli N AU - Amornkul PN FAU - Allen, Susan AU - Allen S FAU - Hunter, Eric AU - Hunter E FAU - Kaslow, Richard A AU - Kaslow RA FAU - Gilmour, Jill AU - Gilmour J FAU - Tang, Jianming AU - Tang J CN - IAVI African HIV Research Network LA - eng GR - AI064060/AI/NIAID NIH HHS/United States GR - 092654/Wellcome Trust/United Kingdom GR - AI071906/AI/NIAID NIH HHS/United States GR - FIC 2D43TW001042/TW/FIC NIH HHS/United States GR - R01 AI071906/AI/NIAID NIH HHS/United States GR - R01 AI064060/AI/NIAID NIH HHS/United States GR - D43 TW001042/TW/FIC NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20130130 PL - United States TA - J Virol JT - Journal of virology JID - 0113724 RN - 0 (HLA-B Antigens) RN - 0 (HLA-B57 antigen) RN - 0 (Host-Derived Cellular Factors) SB - IM MH - Africa, Eastern MH - Analysis of Variance MH - Black People MH - CD4-Positive T-Lymphocytes/immunology MH - Cell Count MH - Cross-Sectional Studies MH - HIV Infections/*immunology MH - *HIV-1 MH - HLA-B Antigens/*metabolism MH - Host-Derived Cellular Factors/*metabolism MH - Humans MH - Immunophenotyping MH - Prospective Studies MH - Sequence Analysis, DNA MH - Viral Load/*immunology MH - Zambia PMC - PMC3624227 EDAT- 2013/02/01 06:00 MHDA- 2013/05/03 06:00 PMCR- 2013/10/01 CRDT- 2013/02/01 06:00 PHST- 2013/02/01 06:00 [entrez] PHST- 2013/02/01 06:00 [pubmed] PHST- 2013/05/03 06:00 [medline] PHST- 2013/10/01 00:00 [pmc-release] AID - JVI.03302-12 [pii] AID - 03302-12 [pii] AID - 10.1128/JVI.03302-12 [doi] PST - ppublish SO - J Virol. 2013 Apr;87(7):4043-51. doi: 10.1128/JVI.03302-12. Epub 2013 Jan 30.